Mankind Pharma Ltd and Innovent Biologics have partnered to license and commercialise the cancer immunotherapy drug Sintilimab in India. They aim to enhance cancer treatment and patient access to innovative therapies. Mankind Pharma plans to seek regulatory approval in 2024 and perform essential clinical trials in India.
